Pharmaceutical company developing next generation of nanomedicines based on an innovative drug delivery platform.
RS Research has raised €12M across 2 funding rounds from 5 investors, most recently a Series A round in Dec 2021. Based in Istanbul, Türkiye; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
| Date |
|---|
| Stage |
|---|
| Amount |
|---|
| Investors |
|---|
| 2021-12-15 | Series A | €11M | Eczacıbaşı Momentum,GEN İlaç,GEN Pharmaceuticals,OneLife Ventures | View deal → |
| 2017-04-24 | Other | €1.1M | ACT Venture Capital | View deal → |
